Find your professional distributor.

Cold Atmospheric Plasma-Aerosol (CAP-A) offers a promising contactless method for skin and wound treatment. This study evaluated its microbiocidal efficacy using the device PLASMO®HEAL, which generates CAP-A. In vitro tests (DIN spec. 91315) against five pathogens showed reductions of 3.4–4.5 log levels (average 4.28). In vivo tests (EN 1500) on human skin using E. coli K12 demonstrated reductions between 4.06 and 5.15 log levels (average 4.82), meeting German VAH standards and matching alcohol-based reference disinfection (average 4.68). CAP-A proved effective, safe, and residue-free, providing a viable non-contact alternative to conventional antiseptics with strong potential for clinical and outpatient wound care. Cold Atmospheric Plasma-Aerosol (CAP-A) was regarded at least as equivalent regarding the microbiocidal effect of direct Cold Atmospheric Plasma (CAP) methods within the framework of metrological traceability. This study was among the first to provide standardized in vitro and in vivo data on the microbiocidal efficacy of CAP-A, using DIN and EN test protocols. Taken together, the results show that the CAP-A method tested can be used in a forward-looking manner in wound care, particularly in the case of microbiological colonization.